Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated I n Vivo

Johann-Christoph Jann, Maximilian Mossner, Vladimir Riabov, Eva Altrock, Nanni Schmitt, Johanna Flach, Qingyu Xu, Verena Nowak, Julia Obländer, Iris Palme, Nadine Weimer, Alexander Streuer, Ahmed Jawhar, Ali Darwich, Georgia Metzgeroth, Florian Nolte, Wolf-Karsten Hofmann, Daniel Nowak

Blood (2021) 138 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2021-150244

Published: 2021

Journal Articles

RNA Sequencing of Bone Marrow Derived Mesenchymal Stromal Cells (MSCs) of Healthy Young, Healthy Old and Patients with Myelodysplastic Syndrome (MDS) Reveals Transcriptomic Changes upon Aging of the Niche and Onset of MDS

Johann-Christoph Jann, Maximilian Mossner, Florian Nolte, MD, Tobias Boch, MD, Verena Nowak, Iris Palme, Julia Obländer, Jovita Pressler, Christina Xanthopoulos, Henning Röhl, MD, Wolf-Karsten Hofmann, MD, Daniel Nowak, MD

Blood (2016) 128 (22): 4300.

https://doi.org/10.1182/blood.V128.22.4300.4300

Published: 2016

Journal Articles

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

Tobias Boch, MD, Thomas Luft, MD PhD, Maximilian Mossner, Johann-Christoph Jann, Daniel Nowak, MD, Christine Folz, Jennifer Klemmer, Susanne Brendel, Harald Fricke, MD, Claudia Kunz, PhD, Wolf-Karsten Hofmann, MD, Florian Nolte, MD

Blood (2016) 128 (22): 228.

https://doi.org/10.1182/blood.V128.22.228.228

Published: 2016

Journal Articles

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

Blood (2016) 128 (9): 1246–1259.

https://doi.org/10.1182/blood-2015-11-679167

Published: 2016

Includes: Supplemental data

Journal Articles

Whole Genome Sequencing of Azole-Resistant Aspergillus Fumigatus Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results

Maximilian Mossner, Birgit Spiess, PhD, Johann-Christoph Jann, Verena Nowak, Julia Obländer, Oliver Bader, Wolf-Karsten Hofmann, MD, Daniel Nowak, MD, Dieter Buchheidt, MD, Tobias Boch, MD

Blood (2015) 126 (23): 4325.

https://doi.org/10.1182/blood.V126.23.4325.4325

Published: 2015

Journal Articles

Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)

Maximilian Mossner, Alexandra Stoehr, Johann-Christoph Jann, Florian Nolte, MD, Verena Nowak, Julia Oblaender, Jovita Pressler, Christina Xanthopoulos, Iris Palme, Claudia D Baldus, MD, Torsten Schulze, MD, Tobias Boch, MD, Georgia Metzgeroth, MD, Martin Neumann, MD, Wolf-Karsten Hofmann, MD, Daniel Nowak, MD

Blood (2015) 126 (23): 2859.

https://doi.org/10.1182/blood.V126.23.2859.2859

Published: 2015

Journal Articles

Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment

Blood (2015) 126 (23): 2891.

https://doi.org/10.1182/blood.V126.23.2891.2891

Published: 2015

Journal Articles

Quantitative Analysis of Patient-Specific Lesions in Primary and Xenografted Myelodysplastic Syndromes Reveals Complex Hierarchies and Subclonal Diversity That Evolve during Disease Progression

Blood (2014) 124 (21): 4604.

https://doi.org/10.1182/blood.V124.21.4604.4604

Published: 2014

Journal Articles

Gene Expression of the Erythroid Regulator Erythroferrone (ERFE) is Highly Deregulated in CD71+ Erythroprogenitor Cells of Patients with Myelodysplastic Syndromes and Demonstrates Prognostic Relevance

Maximilian Mossner, Alexandra Stöhr, Florian Nolte, Johann-Christoph Jann, Stephanie Fey, Verena Nowak, Julia Obländer, Jovita Pressler, Claudia D Baldus, Torsten J Schulze, MD, Martin Neumann, MD, Wolf-Karsten Hofmann, Daniel Nowak

Blood (2014) 124 (21): 4620.

https://doi.org/10.1182/blood.V124.21.4620.4620

Published: 2014

Journal Articles

The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study

Evi launiger-Lörsch, Thomas Luft, Stephanie Fey, Julia Obländer, Susanne Brendel, Jovita Pressler, Johann-Christoph Jann, Claudia Kunz, Anthony D. Ho, Harald Fricke, Maximilian Mossner, Georgia Metzgeroth, Daniel Nowak, Wolf-Karsten Hofmann, Florian Nolte

Blood (2014) 124 (21): 4669.

https://doi.org/10.1182/blood.V124.21.4669.4669

Published: 2014

Journal Articles

Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial

Blood (2014) 124 (21): 1920.

https://doi.org/10.1182/blood.V124.21.1920.1920

Published: 2014

Journal Articles

Development of a DNA-Based Targeted Assay Suitable for Accurate Quantification of Chromosomal Deletions in Myelodysplastic Syndromes with Deletion (5q) and Other Clonal Diseases

Johann-Christoph Jann, Daniel Nowak, Florian Nolte, Stephanie Fey, Verena Nowak, Julia Obländer, Jovita Pressler, Alice Fabarius, PhD, Claudia Haferlach, MD, Hind Medyouf, PhD, Wolf-Karsten Hofmann, Maximilian Mossner

Blood (2014) 124 (21): 1925.

https://doi.org/10.1182/blood.V124.21.1925.1925

Published: 2014

Journal Articles

Next Generation RNA Sequencing of Acute Promyelocytic Leukemia (APL) Identifies Novel Long Non Coding RNAs Including New Variants of MIR181A1HG That Are Differentially Expressed during Myeloid Differentiation

Frederic Lammer, Marion Klaumuenzer, PhD, Maximilian Mossner, Johann Christoph Jann, Anna Hecht, MD, Verena Nowak, Stephanie Fey, Julia Oblaender, Jovita Pressler, Eva Lengfelder, MD, Wolf-Karsten Hofmann, MD PhD, Daniel Nowak, MD

Blood (2014) 124 (21): 1031.

https://doi.org/10.1182/blood.V124.21.1031.1031

Published: 2014

Journal Articles

Molecular Characterization Of The Anti-Leukemic Effects Of Single Agent Eltrombopag

Uwe Platzbecker, MD, PhD, Katja Sockel, MD, Claudia Schönefeldt, Daniel Nowak, MD, Susann Helas, PhD, Christoph Röllig, MD, Maximilian Mossner, Johann-Christoph Jann, Gerhard Ehninger, MD, Wolf-Karsten Hofmann, MD, Martin Bornhäuser, MD, Christian Thiede, MD, Martin Wermke, MD

Blood (2013) 122 (21): 4923.

https://doi.org/10.1182/blood.V122.21.4923.4923

Published: 2013

Journal Articles

TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial

Blood (2013) 122 (21): 2759.

https://doi.org/10.1182/blood.V122.21.2759.2759

Published: 2013

Journal Articles

Array-Based Integrative Analysis Of Epigenomic and Transcriptomic Alterations In CD71+ Bone Marrow Erythroprogenitor Cells From Patients With Myelodysplastic Syndromes

Maximilian Mossner, Axel Wilbertz, Stephanie Fey, Julia Obländer, Verena Nowak, Jovita Vogler, Florian Nolte, MD, Ralf Bieber, Wolf-Karsten Hofmann, MD, Mark Reinwald, MD, Daniel Nowak, MD

Blood (2013) 122 (21): 1561.

https://doi.org/10.1182/blood.V122.21.1561.1561

Published: 2013

Journal Articles

The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS)

Florian Nolte, MD, Claudia Kunz, Stephanie Fey, Julia Obländer, Susanne Brendel, Marion Klaumünzer, Maximilian Mossner, Johann-Christoph Jann, Stefanie Uhlig, Daniel Nowak, MD, Harald Fricke, MD, Wolf-Karsten Hofmann, MD

Blood (2013) 122 (21): 1562.

https://doi.org/10.1182/blood.V122.21.1562.1562

Published: 2013

Journal Articles

Next Generation Sequencing-Based Molecular Dissection Of Lineage-Specific Mutational Hierarchies In Oligoclonal Primary and Xenografted Myelodysplasia

Johann-Christoph Jann, Daniel Nowak, MD, Florian Nolte, MD, Claudia Haferlach, MD, Marita Staller, Verena Nowak, Bettina Zens, Katja Müdder, Corinna Klein, Julia Obländer, Stephanie Fey, Jovita Vogler, Alice Fabarius, PhD, Alexander Kohlmann, PhD, Wolf-Karsten Hofmann, MD, Andreas Trumpp, PhD, Hind Medyouf, PhD, Maximilian Mossner

Blood (2013) 122 (21): 519.

https://doi.org/10.1182/blood.V122.21.519.519

Published: 2013

Journal Articles

MDS-Derived Stromal Cells Exhibit Altered Gene Expression and Support The Engraftment Of lin - CD34 + CD38 - Disease-Initiating Stem Cells In a Xenograft Model Of Lower Risk MDS

Blood (2013) 122 (21): 100.

https://doi.org/10.1182/blood.V122.21.100.100

Published: 2013

Journal Articles

The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories

Blood (2013) 122 (21): 743.

https://doi.org/10.1182/blood.V122.21.743.743

Published: 2013

NARROW

Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated I n Vivo

RNA Sequencing of Bone Marrow Derived Mesenchymal Stromal Cells (MSCs) of Healthy Young, Healthy Old and Patients with Myelodysplastic Syndrome (MDS) Reveals Transcriptomic Changes upon Aging of the Niche and Onset of MDS

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

Whole Genome Sequencing of Azole-Resistant Aspergillus Fumigatus Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results

Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)

Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment

Quantitative Analysis of Patient-Specific Lesions in Primary and Xenografted Myelodysplastic Syndromes Reveals Complex Hierarchies and Subclonal Diversity That Evolve during Disease Progression

Gene Expression of the Erythroid Regulator Erythroferrone (ERFE) is Highly Deregulated in CD71+ Erythroprogenitor Cells of Patients with Myelodysplastic Syndromes and Demonstrates Prognostic Relevance

The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study

Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial

Development of a DNA-Based Targeted Assay Suitable for Accurate Quantification of Chromosomal Deletions in Myelodysplastic Syndromes with Deletion (5q) and Other Clonal Diseases

Next Generation RNA Sequencing of Acute Promyelocytic Leukemia (APL) Identifies Novel Long Non Coding RNAs Including New Variants of MIR181A1HG That Are Differentially Expressed during Myeloid Differentiation

Molecular Characterization Of The Anti-Leukemic Effects Of Single Agent Eltrombopag

TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial

Array-Based Integrative Analysis Of Epigenomic and Transcriptomic Alterations In CD71+ Bone Marrow Erythroprogenitor Cells From Patients With Myelodysplastic Syndromes

The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS)

Next Generation Sequencing-Based Molecular Dissection Of Lineage-Specific Mutational Hierarchies In Oligoclonal Primary and Xenografted Myelodysplasia

MDS-Derived Stromal Cells Exhibit Altered Gene Expression and Support The Engraftment Of lin - CD34 + CD38 - Disease-Initiating Stem Cells In a Xenograft Model Of Lower Risk MDS

The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only